Bianca Domit Werner Linnenkamp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bianca Domit Werner Linnenkamp has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Almeida Andrade
Universidade de São Paulo
6 shared publications - José Eduardo Krieger
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
6 shared publications - Silas Ramos Furquim
Universidade de São Paulo
6 shared publications - Bruno de Oliveira Stephan
Universidade de São Paulo
5 shared publications - Lucas Vieira Lacerda Pires
Universidade de São Paulo
5 shared publications - Bruno Moreira Santos
Universidade de São Paulo
4 shared publications
Latest Publications
- Open Access
- 5 June 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Filamina C e Cardiomiopatias: Ligando Variantes Genéticas ao Seu Impacto Fenotípico
A Filamina C (FLNC) desempenha um papel crítico na manutenção da integridade estrutural das células musculares, particularmente dentro do sarcômero cardíaco. Variantes patogênicas no gene FLNC são cada vez mais reconhecidas como contribuintes significativos para uma gama diversificada de cardiomiopatias, incluindo cardiomiopatia dilatada (CMD), hipertrófica (CMH), arritmogênica (CMA) e restritiva (CMR). Esta revisão explora as correlações genótipo-fenótipo em cardiomiopatias relacionadas ao gene FLNC, enfatizando como o tipo e a localização das variantes genéticas influenciam a apresentação clínica. Variantes truncadas são principalmente associadas a CMD e CMA, caracterizadas por um alto risco de eventos arrítmicos e resultados graves, enquanto variantes missense frequentemente levam a CMH e CMR, com características fenotípicas únicas. A revisão também discute os padrões de herança, mecanismos moleculares e fenótipos clínicos de miopatias associadas à FLNC, destacando a necessidade de testes genéticos na estratificação e gestão de risco. Perspectivas futuras enfatizam a importância de expandir a pesquisa sobre os mecanismos subjacentes das variantes em filamina C e suas interações com outros fatores genéticos e ambientais. Essa compreensão integrada é crítica para melhorar o gerenciamento clínico de pacientes com cardiomiopatias relacionadas a FLNC.
- 5 June 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Open AccessFilamina C e Cardiomiopatias: Ligando Variantes Genéticas ao Seu Impacto Fenotípico
A Filamina C (FLNC) desempenha um papel crítico na manutenção da integridade estrutural das células musculares, particularmente dentro do sarcômero cardíaco. Variantes patogênicas no gene FLNC são cada vez mais reconhecidas como contribuintes significativos para uma gama diversificada de cardiomiopatias, incluindo cardiomiopatia dilatada (CMD), hipertrófica (CMH), arritmogênica (CMA) e restritiva (CMR). Esta revisão explora as correlações genótipo-fenótipo em cardiomiopatias relacionadas ao gene FLNC, enfatizando como o tipo e a localização das variantes genéticas influenciam a apresentação clínica. Variantes truncadas são principalmente associadas a CMD e CMA, caracterizadas por um alto risco de eventos arrítmicos e resultados graves, enquanto variantes missense frequentemente levam a CMH e CMR, com características fenotípicas únicas. A revisão também discute os padrões de herança, mecanismos moleculares e fenótipos clínicos de miopatias associadas à FLNC, destacando a necessidade de testes genéticos na estratificação e gestão de risco. Perspectivas futuras enfatizam a importância de expandir a pesquisa sobre os mecanismos subjacentes das variantes em filamina C e suas interações com outros fatores genéticos e ambientais. Essa compreensão integrada é crítica para melhorar o gerenciamento clínico de pacientes com cardiomiopatias relacionadas a FLNC.
- Open Access
- 1 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Filamin C and Cardiomyopathies: Linking Genetic Variants to Their Phenotypic Impact
Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and [...] Abstract Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and
- 1 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (2)
Open AccessFilamin C and Cardiomyopathies: Linking Genetic Variants to Their Phenotypic Impact
Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and [...] Abstract Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and
- Open Access
- 1 April 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Explorando o Papel das Variantes do ALPK3 em Cardiomiopatias Hipertróficas e Dilatadas
As variantes do gene ALPK3 (proteína alfa-quinase 3), em especial as variantes truncadas (ALPK3tv), têm sido associadas à cardiomiopatia hipertrófica (CMH) e à cardiomiopatia dilatada (CMD), contribuindo para a variabilidade fenotípica e para resultados clínicos graves. A CMH é caracterizada por uma hipertrofia ventricular esquerda não atribuível a outras causas, sendo uma condição genética comum, ligada frequentemente a variantes patogênicas em genes de sarcômeros. No entanto, em aproximadamente 40% dos casos, os testes genéticos não são capazes de identificar uma variante causal, o que sugere o envolvimento de genes não sarcoméricos, como o ALPK3. Estudos recentes revelam que a ALPK3tv bialélica está associada à cardiomiopatia grave de início precoce. Os pacientes podem apresentar uma progressão clínica da CMD na infância para a CMH, com função sistólica prejudicada na vida adulta. Nesses indivíduos, o fenótipo da CMH é caracterizado, em geral, por fibrose miocárdica extensa, padrões apicais ou concêntricos de hipertrofia ventricular esquerda e baixa prevalência de obstrução do trato de saída do ventrículo esquerdo. Os portadores de ALPK3tv também correm o risco de desenvolver disfunção miocárdica progressiva, insuficiência cardíaca e, em alguns casos, morte cardíaca súbita. Os mecanismos moleculares subjacentes à cardiomiopatia relacionada ao ALPK3 envolvem a interrupção de proteínas estruturais e regulatórias, como as miomesinas, essenciais para a integridade do sarcômero e o controle da força dos cardiomiócitos. A descoberta das variantes do gene ALPK3 em populações sub-representadas destaca a importância da pesquisa genética em diversas coortes. A compreensão das consequências clínicas e moleculares das variantes do gene ALPK3 pode resultar em abordagens diagnósticas e terapêuticas mais precisas para cardiomiopatias associadas a esse gene.
- 1 April 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Open AccessExplorando o Papel das Variantes do ALPK3 em Cardiomiopatias Hipertróficas e Dilatadas
As variantes do gene ALPK3 (proteína alfa-quinase 3), em especial as variantes truncadas (ALPK3tv), têm sido associadas à cardiomiopatia hipertrófica (CMH) e à cardiomiopatia dilatada (CMD), contribuindo para a variabilidade fenotípica e para resultados clínicos graves. A CMH é caracterizada por uma hipertrofia ventricular esquerda não atribuível a outras causas, sendo uma condição genética comum, ligada frequentemente a variantes patogênicas em genes de sarcômeros. No entanto, em aproximadamente 40% dos casos, os testes genéticos não são capazes de identificar uma variante causal, o que sugere o envolvimento de genes não sarcoméricos, como o ALPK3. Estudos recentes revelam que a ALPK3tv bialélica está associada à cardiomiopatia grave de início precoce. Os pacientes podem apresentar uma progressão clínica da CMD na infância para a CMH, com função sistólica prejudicada na vida adulta. Nesses indivíduos, o fenótipo da CMH é caracterizado, em geral, por fibrose miocárdica extensa, padrões apicais ou concêntricos de hipertrofia ventricular esquerda e baixa prevalência de obstrução do trato de saída do ventrículo esquerdo. Os portadores de ALPK3tv também correm o risco de desenvolver disfunção miocárdica progressiva, insuficiência cardíaca e, em alguns casos, morte cardíaca súbita. Os mecanismos moleculares subjacentes à cardiomiopatia relacionada ao ALPK3 envolvem a interrupção de proteínas estruturais e regulatórias, como as miomesinas, essenciais para a integridade do sarcômero e o controle da força dos cardiomiócitos. A descoberta das variantes do gene ALPK3 em populações sub-representadas destaca a importância da pesquisa genética em diversas coortes. A compreensão das consequências clínicas e moleculares das variantes do gene ALPK3 pode resultar em abordagens diagnósticas e terapêuticas mais precisas para cardiomiopatias associadas a esse gene.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Desvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3) , e20240444
Open AccessDesvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé
Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Unveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Open AccessUnveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome
A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Exploring the Role of ALPK3 Variants in Hypertrophic and Dilated Cardiomyopathies
Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such [...] Abstract Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (1)
Open AccessExploring the Role of ALPK3 Variants in Hypertrophic and Dilated Cardiomyopathies
Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such [...] Abstract Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such
- Open Access
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
O Papel das Variantes no Gene TTN na Cardiomiopatia Dilatada
A titina, codificada pelo gene TTN, é a maior proteína humana, essencial para a manutenção da estabilidade das células musculares e regulação da contração miocárdica. As variantes truncadas do TTN (TTNtv) têm sido consideradas a causa genética mais comum de cardiomiopatia dilatada (CMD), respondendo por até 25% dos casos familiares e 18% dos casos esporádicos. Esta revisão examina a relação complexa entre as variantes no gene TTN e a CMD, destacando os desafios impostos pela penetrância incompleta e a expressividade variável. Embora as variantes truncadas, principalmente na região da banda A, estejam ligadas à CMD, nem todos os portadores apresentam sintomas clínicos, indicando a influência de fatores genéticos e ambientais adicionais. Além disso, discutimos as implicações prognósticas das variantes no gene TTN, que, apesar dos resultados clínicos semelhantes a outros casos de CMD, demonstram uma taxa maior de remodelação reverso em resposta ao tratamento da insuficiência cardíaca. Estratégias terapêuticas emergentes, que visam mecanismos moleculares subjacentes das variantes no gene TTN, incluindo inibidores de mTOR e edição genética baseada em CRISPR, oferecem possibilidades promissoras para um tratamento personalizado. Compreender os fundamentos genéticos da CMD relacionada ao TTN é crucial para melhorar o diagnóstico, o rastreamento familiar e os resultados terapêuticos, abrindo caminho para um manejo mais eficaz desse quadro complexo.
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
Open AccessO Papel das Variantes no Gene TTN na Cardiomiopatia Dilatada
A titina, codificada pelo gene TTN, é a maior proteína humana, essencial para a manutenção da estabilidade das células musculares e regulação da contração miocárdica. As variantes truncadas do TTN (TTNtv) têm sido consideradas a causa genética mais comum de cardiomiopatia dilatada (CMD), respondendo por até 25% dos casos familiares e 18% dos casos esporádicos. Esta revisão examina a relação complexa entre as variantes no gene TTN e a CMD, destacando os desafios impostos pela penetrância incompleta e a expressividade variável. Embora as variantes truncadas, principalmente na região da banda A, estejam ligadas à CMD, nem todos os portadores apresentam sintomas clínicos, indicando a influência de fatores genéticos e ambientais adicionais. Além disso, discutimos as implicações prognósticas das variantes no gene TTN, que, apesar dos resultados clínicos semelhantes a outros casos de CMD, demonstram uma taxa maior de remodelação reverso em resposta ao tratamento da insuficiência cardíaca. Estratégias terapêuticas emergentes, que visam mecanismos moleculares subjacentes das variantes no gene TTN, incluindo inibidores de mTOR e edição genética baseada em CRISPR, oferecem possibilidades promissoras para um tratamento personalizado. Compreender os fundamentos genéticos da CMD relacionada ao TTN é crucial para melhorar o diagnóstico, o rastreamento familiar e os resultados terapêuticos, abrindo caminho para um manejo mais eficaz desse quadro complexo.
- Open Access
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
The Role of TTN Gene Variants in Dilated Cardiomyopathy
Titin, encoded by the TTN gene, is the largest human protein, essential for maintaining muscle cell stability and regulating myocardial contraction. TTN truncating variants (TTNtv) have emerged as the most common genetic cause of dilated cardiomyopathy (DCM), accounting for up to 25% of familial cases and 18% of sporadic cases. This review examines the complex relationship between TTN variants and DCM, highlighting the challenges posed by incomplete penetrance and variable expressivity. While truncating variants primarily in the A-band region [...] Abstract Titin, encoded by the TTN gene, is the largest human protein, essential for maintaining muscle cell stability and regulating myocardial contraction. TTN truncating variants (TTNtv) have emerged as the most common genetic cause of dilated cardiomyopathy (DCM), accounting for up to 25% of familial cases and 18% of sporadic cases. This review examines the complex relationship between TTN variants and DCM, highlighting the challenges posed by incomplete penetrance and variable expressivity. While truncating variants primarily in the A-band region
- 18 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (3)
Open AccessThe Role of TTN Gene Variants in Dilated Cardiomyopathy
Titin, encoded by the TTN gene, is the largest human protein, essential for maintaining muscle cell stability and regulating myocardial contraction. TTN truncating variants (TTNtv) have emerged as the most common genetic cause of dilated cardiomyopathy (DCM), accounting for up to 25% of familial cases and 18% of sporadic cases. This review examines the complex relationship between TTN variants and DCM, highlighting the challenges posed by incomplete penetrance and variable expressivity. While truncating variants primarily in the A-band region [...] Abstract Titin, encoded by the TTN gene, is the largest human protein, essential for maintaining muscle cell stability and regulating myocardial contraction. TTN truncating variants (TTNtv) have emerged as the most common genetic cause of dilated cardiomyopathy (DCM), accounting for up to 25% of familial cases and 18% of sporadic cases. This review examines the complex relationship between TTN variants and DCM, highlighting the challenges posed by incomplete penetrance and variable expressivity. While truncating variants primarily in the A-band region
- 17 September 2024
- Published by S. Karger AG in Molecular Syndromology
- Vol. 16 (2) , 1-7
Coexistence of Rare Genetic Disorders in a Consanguineous Family: Case Study of KLHL24-Related Hypertrophic Cardiomyopathy and Char Syndrome
Introduction: Physicians often search for a single underlying cause that explains all of a patient’s signs and symptoms. However, evidence from the literature suggests that the concurrent presence of two rare diseases, although uncommon, poses significant diagnostic challenges. Precision medicine is increasingly important in these scenarios, enabling more rapid diagnosis and tailored treatments. Case Presentation: This report discusses a patient involving a consanguineous Brazilian family, where two sisters are diagnosed with autosomal recessive KLHL24-related hypertrophic cardiomyopathy. Additionally, one sister is diagnosed with Char syndrome due to a TFAP2B deletion. Conclusion: This case underscores the possibility that multiple rare genetic disorders can coexist, contributing to complex clinical phenotypes. Whole-exome sequencing proves to be a critical tool in identifying the genetic underpinnings of such complex cases, facilitating precise diagnosis and genetic counseling. The discovery of a homozygous KLHL24 variant further broadens the known mutation spectrum and underscores its significance in autosomal recessive hypertrophic cardiomyopathy.
- 17 September 2024
- Published by S. Karger AG in Molecular Syndromology
- Vol. 16 (2) , 1-7
Coexistence of Rare Genetic Disorders in a Consanguineous Family: Case Study of KLHL24-Related Hypertrophic Cardiomyopathy and Char Syndrome
Introduction: Physicians often search for a single underlying cause that explains all of a patient’s signs and symptoms. However, evidence from the literature suggests that the concurrent presence of two rare diseases, although uncommon, poses significant diagnostic challenges. Precision medicine is increasingly important in these scenarios, enabling more rapid diagnosis and tailored treatments. Case Presentation: This report discusses a patient involving a consanguineous Brazilian family, where two sisters are diagnosed with autosomal recessive KLHL24-related hypertrophic cardiomyopathy. Additionally, one sister is diagnosed with Char syndrome due to a TFAP2B deletion. Conclusion: This case underscores the possibility that multiple rare genetic disorders can coexist, contributing to complex clinical phenotypes. Whole-exome sequencing proves to be a critical tool in identifying the genetic underpinnings of such complex cases, facilitating precise diagnosis and genetic counseling. The discovery of a homozygous KLHL24 variant further broadens the known mutation spectrum and underscores its significance in autosomal recessive hypertrophic cardiomyopathy.
- Open Access
- 8 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8648
Evaluation of 73 Enlisted Patients for Liver Transplant with Unknown Etiology Reveals a Late-Diagnosed Case of Lysosomal Acid Lipase Deficiency
Lysosomal acid lipase deficiency (LALD) varies from a severe infantile-onset form (Wolman disease) to a late-onset form known as cholesteryl ester storage disease (CESD), both of which are autosomal recessive disorders caused by biallelic LIPA pathogenic variants. We evaluated seventy-three patients enlisted for liver transplant (LT) at Instituto da Criança (HCFMUSP—Brazil) who were subjected to LAL activity measurement and LIPA Sanger sequencing analysis, resulting in a positive LALD diagnosis for only one of these individuals. This LALD patient presented recurrent diarrhea, failure to thrive, hepatomegaly, and dyslipidemia at the age of 4 months and liver failure by the age of 13 years. The LALD diagnosis confirmation was conducted at 24 years old due to low levels of LAL enzyme activity. The causal homozygous variant LIPA(NM_000235.4):c.266T>C(p.Leu89Pro) was identified, but the patient had already undergone his first LT at 18 years with several rejection episodes. Despite beginning treatment with sebelipase alfa at 26 years old (total of five infusions), this patient died at 28 years from complications after his second liver transplant. LALD is an important differential diagnosis in cases presenting with hepatomegaly, elevated liver enzymes, and dyslipidemia. Detecting low/absent LAL activity and identifying the LIPA causal variant are essential for diagnosis and specific treatment, as well as for appropriate genetic counseling. Early diagnosis, along with sebelipase alfa therapy, may improve the prognosis of affected patients.
- 8 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8648
Open AccessEvaluation of 73 Enlisted Patients for Liver Transplant with Unknown Etiology Reveals a Late-Diagnosed Case of Lysosomal Acid Lipase Deficiency
Lysosomal acid lipase deficiency (LALD) varies from a severe infantile-onset form (Wolman disease) to a late-onset form known as cholesteryl ester storage disease (CESD), both of which are autosomal recessive disorders caused by biallelic LIPA pathogenic variants. We evaluated seventy-three patients enlisted for liver transplant (LT) at Instituto da Criança (HCFMUSP—Brazil) who were subjected to LAL activity measurement and LIPA Sanger sequencing analysis, resulting in a positive LALD diagnosis for only one of these individuals. This LALD patient presented recurrent diarrhea, failure to thrive, hepatomegaly, and dyslipidemia at the age of 4 months and liver failure by the age of 13 years. The LALD diagnosis confirmation was conducted at 24 years old due to low levels of LAL enzyme activity. The causal homozygous variant LIPA(NM_000235.4):c.266T>C(p.Leu89Pro) was identified, but the patient had already undergone his first LT at 18 years with several rejection episodes. Despite beginning treatment with sebelipase alfa at 26 years old (total of five infusions), this patient died at 28 years from complications after his second liver transplant. LALD is an important differential diagnosis in cases presenting with hepatomegaly, elevated liver enzymes, and dyslipidemia. Detecting low/absent LAL activity and identifying the LIPA causal variant are essential for diagnosis and specific treatment, as well as for appropriate genetic counseling. Early diagnosis, along with sebelipase alfa therapy, may improve the prognosis of affected patients.